Rodríguez García, José A.Caballero García, María DoloresGutiérrez García, Antonio ManuelGandarillas, MarcoSierra Gil, JorgeLópez Guillermo, ArmandoZuazu, JavierMarín Solano, JesúsArranz, ReyesCarreras Gómez, EnricLeón, ÁngelFernández de Sevilla Ribosa, AlbertoSan Miguel, Jesús F.Conde, EulogioGEL/TAMO Spanish Group2020-12-152020-12-152003-12-010390-6078https://hdl.handle.net/2445/172745Background and objectives: patients with aggressive non-Hodgkin's lymphomas (NHL) who do not obtain a complete response (CR) after induction chemotherapy have a poor prognosis. However, provided they are sensitive to the first regimen of chemotherapy, 25-40% of them with a B-cell phenotype may achieve long-term survival when treated with high dose chemotherapy and autologous stem cell transplantation (HDC/ASCT). The aim of this study was to analyze the efficacy of this therapy in the corresponding patients with peripheral T-cell lymphoma (PTCL). Design and methods: we retrospectively evaluated the efficacy of ASCT in 35 patients with PTCL from the GEL-TAMO registry, who did not achieve a CR to standard induction chemotherapy regimens for aggressive NHL. Thirty-one patients underwent transplantation after achieving a partial response (PR) and 4 patients were non-responders. Results: following HDC/ASCT, 23 (66%) of the patients achieved a CR, 4 (11%) a PR and in 7 (20%) cases the transplant failed. One patient was not evaluated because of early toxic death. With a median follow-up of the survivors of 37.5 months, 18 patients (51%) are alive and 15 patients (43%) are free of disease. Transplant-related mortality rate at 100 days was 11% and at 5 years the probabilities of survival, freedom from progression and disease-free survival for complete responders were 37%, 36% and 55% respectively. Pre-transplant lactate-dehydrogenase level, age-adjusted International Prognostic Index (aa-IPI) and tumor score correlated with survival. Interpretation and conclusions: one third of the patients with PTCL who fail to achieve CR to the first chemotherapeutic regimen can be rescued with HDC/ASCT. Pre-transplant values of IPI and tumor score risk systems for aggressive lymphomas were useful to predict subsequent survival.6 p.application/pdfeng(c) Ferrata Storti Foundation, 2003Ús terapèuticLimfomesCèl·lules TCèl·lules mareTherapeutic useLymphomasT cellsStem cellsinfo:eu-repo/semantics/article5190092020-12-15info:eu-repo/semantics/openAccess14687990